Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond
P.N. Praveen Rao,Edward E. Knaus +1 more
Reads0
Chats0
TLDR
This review traces the origins of NSAIDs, their mechanism of action at the molecular level such as cyclooxygenase (COX) inhibition, development of selective COX-2 inhibitors, their adverse cardiovascular effects, and some recent developments targeted to the design of effective anti-inflammatory agents with reduced side effects.Abstract:
Purpose. NSAIDs constitute an important class of drugs with therapeutic applications that have spanned several centuries. Treatment of inflammatory conditions such as rheumatoid arthritis (RA) and osteoarthritis (OA) starting from the classic drug aspirin to the recent rise and fall of selective COX-2 inhibitors has provided an enthralling evolution. Efforts to discover an ultimate magic bullet to treat inflammation continues to be an important drug design challenge. This review traces the origins of NSAIDs, their mechanism of action at the molecular level such as cyclooxygenase (COX) inhibition, development of selective COX-2 inhibitors, their adverse cardiovascular effects, and some recent developments targeted to the design of effective anti-inflammatory agents with reduced side effects. Methods. Literature data is presented describing important discoveries pertaining to the sequential development of classical NSAIDs and then selective COX-2 inhibitors, their mechanism of action, the structural basis for COX inhibition, and recent discoveries. Results. A brief history of the development of NSAIDs and the market withdrawal of selective COX-2 inhibitors is explained, followed by the description of prostaglandin biosynthesis, COX isoforms, structure and function. The structural basis for COX-1 and COX-2 inhibition is described along with methods used to evaluate COX-1/COX-2 inhibition. This is followed by a section that encompasses the major chemical classes of selective COX-2 inhibitors. The final section describes briefly some of the recent advances toward developing effective anti-inflammatory agents such as nitric oxide donor NO-NSAIDs, dual COX/LOX inhibitors and anti-TNF therapy. Conclusions. A great deal of progress has been made toward developing novel anti-inflammatory agents. In spite of the tremendous advances in the last decade, the design and development of a safe, effective and economical therapy for treating inflammatory conditions still presents a major challenge.read more
Citations
More filters
Journal ArticleDOI
Pharmacogenomics of cyclooxygenases.
TL;DR: This work analyses major variations in the PTGS1 and PTGS2 genes, allele frequencies, functional consequences and population genetics, and provides an up-to-date catalog of PTGS clinical associations based on case-control studies and genome-wide association studies, and future research suggestions.
Journal ArticleDOI
Switching the microglial harmful phenotype promotes lifelong restoration of subtantia nigra dopaminergic neurons from inflammatory neurodegeneration in aged mice.
Francesca L'Episcopo,Cataldo Tirolo,Nunzio Testa,Salvatore Caniglia,Maria C. Morale,Francesco Impagnatiello,Bianca Marchetti +6 more
TL;DR: A treatment in which the effects of nitric oxide with nonsteroidal antiinflammatory activity are combined by using HCT1026, a NO-donating derivative of flurbiprofen that has a safe profile and additional immunomodulatory properties and underscoring glia as a key pharmacological target for DAergic neuroprotection.
Journal ArticleDOI
Prediction of Anti-inflammatory Plants and Discovery of Their Biomarkers by Machine Learning Algorithms and Metabolomic Studies.
Daniela Aparecida Chagas-Paula,Tiago Branquinho Oliveira,Tong Zhang,RuAngelie Edrada-Ebel,Fernando B. Da Costa +4 more
TL;DR: The biomarkers of the Asteraceae extracts were statistically correlated with their anti-inflammatory activities and can therefore be useful to predict new anti- inflammatory extracts and theirAnti-inflammatory compounds using only liquid chromatography-mass spectrometry data.
Journal ArticleDOI
Activation of CF Bonds in Preference to CI Bonds: Difluoromethylation of Lithium Enolates with Trifluoromethyl Iodide
Journal ArticleDOI
Investigational drugs targeting the prostaglandin E2 signaling pathway for the treatment of inflammatory pain.
TL;DR: This review gives an overview about the first and second generations of NSAIDs (COX1/2 non-selective, COX-2 selective), and their main side effects which gave still an urgent need for safer drugs and for the establishment of novel treatment strategies.
References
More filters
Journal ArticleDOI
Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs
TL;DR: Experiments with guinea-pig lung suggest that some of the therapeutic effects of sodium salicylate and aspirin-like drugs are due to inhibition of the synthesis of prostaglandins.
Journal ArticleDOI
Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis
Claire Bombardier,Loren Laine,Alise S. Reicin,Deborah R. Shapiro,Ruben Burgos-Vargas,Barry R. Davis,Richard O. Day,Marcos Bosi Ferraz,Christopher J. Hawkey,Marc C. Hochberg,Tore K Kvien,Thomas J. Schnitzer +11 more
TL;DR: In patients with rheumatoid arthritis, treatment with rofecoxib, a selective inhibitor of cyclooxygenase-2, is associated with significantly fewer clinically important upper gastrointestinal events than treatment with naproxen, a nonselective inhibitor.
Journal ArticleDOI
Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis: The CLASS Study: A Randomized Controlled Trial
Fred E. Silverstein,Gerald A. Faich,Jay L. Goldstein,Lee S. Simon,Theodore Pincus,Andrew Whelton,Robert W. Makuch,Glenn M. Eisen,Naurang M. Agrawal,William F. Stenson,Aimee M. Burr,William W. Zhao,Jeffrey D. Kent,James B. Lefkowith,Kenneth M. Verburg,G. Steven Geis +15 more
TL;DR: In this study, celecoxib, at dosages greater than those indicated clinically, was associated with a lower incidence of symptomatic ulcers and ulcer complications combined, as well as other clinically important toxic effects, compared with NSAIDs at standard dosages.
Journal ArticleDOI
Cyclooxygenases: Structural, cellular, and molecular biology
TL;DR: This review examines how the structures of these enzymes relate mechanistically to cyclooxygenase and peroxidase catalysis, and how differences in the structure of PGHS-2 confer on this isozyme differential sensitivity to COX-2 inhibitors.
Journal ArticleDOI
Cyclooxygenases 1 and 2
TL;DR: The discovery ofCOX-2 has made possible the design of drugs that reduce inflammation without removing the protective PGs in the stomach and kidney made by COX-1, which may not only be anti-inflammatory but may also be active in colon cancer and Alzheimer's disease.